Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q7KZF4
UPID:
SND1_HUMAN
Alternative names:
100 kDa coactivator; EBNA2 coactivator p100; Tudor domain-containing protein 11; p100 co-activator
Alternative UPACC:
Q7KZF4; Q13122; Q96AG0
Background:
Staphylococcal nuclease domain-containing protein 1, also known as Tudor domain-containing protein 11 and p100 co-activator, plays a pivotal role in miRNA decay, impacting mRNA regulation during the G1-to-S phase transition. It acts as a bridge between STAT6 and basal transcription factors, and is involved in the regulation of MYB activity by PIM1. Additionally, it functions as a transcriptional coactivator for STAT5 and the Epstein-Barr virus nuclear antigen 2 (EBNA2).
Therapeutic significance:
Understanding the role of Staphylococcal nuclease domain-containing protein 1 could open doors to potential therapeutic strategies.